Spondyloarthritis News and Research

RSS

FDA approves treatment for adults with non-radiographic axial spondyloarthritis

The U.S. Food and Drug Administration today approved Cimzia (certolizumab pegol) injection for treatment of adults with a certain type of inflammatory arthritis called non-radiographic axial spondyloarthritis (nr-axSpA), with objective signs of inflammation. This is the first time that the FDA has approved a treatment for nr-axSpA.

28 Mar 2019

Unconventional T cells may account for failure of IL-17 inhibition in rheumatoid arthritis

Spondyloarthritis is one of the most common types of chronic joint inflammation affecting nearly 1-2% of the Western population.

10 Jan 2019

New study launched to examine effects of rheumatologic agent on bone health

Researchers at Hospital for Special Surgery have launched a pilot study to see how a drug that treats several related autoimmune disorders affects the skeleton.

7 May 2018

Bone marrow edema does not increase due to intense physical activity, study finds

A recent study published in Rheumatology finds that osteitis/bone marrow edema as measured by magnetic resonance imaging was present in healthy people. However, it did not significantly increase due to intense physical activity.

14 Dec 2017

MRI scans of healthy military recruits reveal sacroiliac joint damage that mimics axial spondyloarthritis

The magnetic resonance imaging scans of healthy military recruits showed sacroiliac joint damage similar to that found in axial spondyloarthritis after just six weeks of intensive physical training, reinforcing the importance of exercising caution when interpreting MRI results, according to new research findings presented this week at the 2017 ACR/ARHP Annual Meeting in San Diego.

6 Nov 2017

New guidelines for anti-rheumatic drug management in patients having joint replacement surgery

In the first such collaboration of its kind, an expert panel of rheumatologists and orthopedic surgeons has developed guidelines for the perioperative management of anti-rheumatic medication in patients undergoing total hip or knee replacement.

16 Jun 2017

ACR, AAHKS release new guideline to reduce joint infections after total hip and knee replacements

According to a new guideline released by the American College of Rheumatology and American Association of Hip and Knee Surgeons, the risk of joint infection resulting from total hip and knee replacements can be reduced with careful management of anti-rheumatic medications during the perioperative process.

16 Jun 2017

BSR and RCGP introduce joint project to improve care for people with inflammatory arthritis

BSR and the RCGP have today launched a joint Quality Improvement project to improve care for people living with inflammatory arthritis.

10 May 2017

Researchers identify E. coli bacteria linking Crohn's disease to spondyloarthritis

Patients with Crohn's disease, a type of inflammatory bowel disease (IBD) that causes abdominal pain and diarrhea, can also experience joint pain.

9 Feb 2017

Research finding opens door to new treatment options for inflammatory rheumatism

Enthesitis, inflammation of tendons where they attach to the bone, is a common medical problem which underlies various forms of inflammatory rheumatism.

23 Aug 2016

Antibody-positive patients treated with infliximab less likely to benefit from infliximab biosimilar

The results of a study presented today at the European League Against Rheumatism Annual Congress showed that when antibodies develop in response to the biological treatment Remicade (infliximab), they also cross-react with the biosimilar of infliximab (CT-P13: Inflectra or Remsima).

10 Jun 2016

BENEPALI granted marketing authorization in the EU for treatment of chronic inflammatory diseases

The joint venture between Biogen and Samsung BioLogics, Samsung Bioepis, has been granted European Commission (EC) approval for BENEPALI , an etanercept biosimilar referencing Enbrel.

19 Jan 2016

Novartis announces FDA approval of Cosentyx for treatment of adult patients with AS and PsA

Novartis announced today that the US Food and Drug Administration has approved Cosentyx (secukinumab) for two new indications - the treatment of adult patients with active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA).

17 Jan 2016

NEJM publishes results of Cosentyx Phase III studies in ankylosing spondylitis

Novartis announced today that the results of the MEASURE 1 and MEASURE 2 Phase III studies for Cosentyx® (secukinumab) in ankylosing spondylitis (AS) were published in The New England Journal of Medicine (NEJM). These pivotal studies demonstrated significant clinical improvements with Cosentyx versus placebo in reducing the signs and symptoms of active AS – a long-term, painful and debilitating inflammation of the spine.

24 Dec 2015

Novartis’ Cosentyx® show no progression in spinal damage in 80% of ankylosing spondylitis patients

Novartis announced today late-breaking two year results for Cosentyx® (secukinumab) showing up to 80% of patients with ankylosing spondylitis (AS) had no radiographic progression in the spine on x-ray assessment. This is the first time that data on structural spinal progression in AS have been presented for an interleukin-17A (IL-17A) inhibitor.

9 Nov 2015

Spondyloarthritis News and Research

FDA approves treatment for adults with non-radiographic axial spondyloarthritis

Unconventional T cells may account for failure of IL-17 inhibition in rheumatoid arthritis

New study launched to examine effects of rheumatologic agent on bone health

Bone marrow edema does not increase due to intense physical activity, study finds

MRI scans of healthy military recruits reveal sacroiliac joint damage that mimics axial spondyloarthritis

New guidelines for anti-rheumatic drug management in patients having joint replacement surgery

ACR, AAHKS release new guideline to reduce joint infections after total hip and knee replacements

BSR and RCGP introduce joint project to improve care for people with inflammatory arthritis

Researchers identify E. coli bacteria linking Crohn's disease to spondyloarthritis

Research finding opens door to new treatment options for inflammatory rheumatism

Antibody-positive patients treated with infliximab less likely to benefit from infliximab biosimilar

BENEPALI granted marketing authorization in the EU for treatment of chronic inflammatory diseases

Novartis announces FDA approval of Cosentyx for treatment of adult patients with AS and PsA

NEJM publishes results of Cosentyx Phase III studies in ankylosing spondylitis

Novartis’ Cosentyx® show no progression in spinal damage in 80% of ankylosing spondylitis patients

ACR releases new recommendations for treatment of AS and non-radiographic axial SpA

MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

Crescendo Bioscience to present new data on Vectra DA at ACR Annual Meeting

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

FDA approves Cimzia (certolizumab pegol) for active psoriatic arthritis

Industry Focus eBook - Cell biology (5th edition) eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News